All In Biotech

Drug Trial Radar · NCT00775996

Bioequivalence Study of Clorazepate Dipotassium 15mg Tablets Under Fasting Conditions

The Objective of This Study Was to Compare the Single-Dose Relative Bioavailability of Ranbaxy and Abbott (Tranxene® T-Tab®) 15 mg Clorazepate Dipotassium Tablets Under Fasting Conditions.

Last checked: Nov 20, 2026Latest source record: Oct 20, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Aug 2003

Primary completion

Sep 2003

Study completion Nov 2003

Sponsor

Lead sponsor
Ranbaxy Laboratories LimitedIndustry
Sponsor type
Industry
First posted
Oct 20, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Crossover
Masking
None
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Abbott (TranxeneeT-Tab®) 15 mg clorazepate dipotassium tablets under fasting conditions.

Conditions

  • Healthy

Interventions

  • Clorazepate Dipotassium 15mg TabletsDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Bioequivalence

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MDS Pharma Services

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.